Annovis Bio to Present Buntanetap Data in November
The Malvern-based company will share findings at the 19th Clinical Trials on Alzheimer's Disease conference.
Updated on Oct. 28, 2026 in Alzheimer’s
Live Poll
Do you feel optimistic that new drug research will lead to effective Alzheimer's treatments?
Annovis Bio Inc. is scheduled to deliver three presentations on its investigational Alzheimer's drug, buntanetap, at the 19th Clinical Trials on Alzheimer's Disease conference beginning November 16, 2026. These updates serve as a precursor to the company's anticipated Phase 3 clinical trial data readout expected in early 2027.
Why it matters
The upcoming presentations provide critical insight into the drug's progress ahead of a planned New Drug Application to the U.S. Food and Drug Administration. These findings are essential for evaluating the potential of buntanetap as an oral therapy for neurodegenerative conditions.
Annovis Bio will hold three distinct sessions at the conference, including an oral presentation on the mechanism of action for buntanetap. The drug is currently being tested in patients with early Alzheimer's disease to inhibit the production of neurotoxic proteins.
The players
Annovis Bio Inc.
A clinical-stage drug platform company based in Malvern, Pennsylvania, that specializes in developing treatments for neurodegenerative diseases.
U.S. Food and Drug Administration
The federal agency responsible for protecting public health by regulating the safety, efficacy, and security of human and veterinary drugs.
The details
The presentations in Boston cover trial design, AI research, and the drug's mechanism of action in inhibiting neurotoxic protein translation. Malvern, Pennsylvania-based Annovis Bio Inc. is also developing the therapy for Parkinson's disease.
Timeline
Poster sessions regarding trial design and AI research occur November 16-17, 2026.
The 19th Clinical Trials on Alzheimer's Disease conference is held November 16-19, 2026.
An oral presentation on the drug's mechanism occurs November 19, 2026, at 3:52 p.m. ET.
The Phase 3 clinical trial data readout is anticipated in early 2027.
Health Landscape
These disclosures follow the established pathway of the U.S. Food and Drug Administration's New Drug Application process for pharmaceutical approval. The company's strategy reflects the broader trend of using interim data presentations to signal clinical progress to stakeholders before final regulatory reviews.
Patients and families affected by early-stage Alzheimer's should note that this drug remains in the clinical trial phase, with full results not expected until 2027. No immediate changes to standard treatment protocols or medication availability are currently authorized.
The takeaway
The data presented in Boston will serve as a bellwether for the future of buntanetap as a potential oral Alzheimer's treatment. Observers should track the upcoming 2027 readout to understand how this therapy might eventually fit into clinical care standards.
Further reading
Learn more about the latest research and ongoing studies in Alzheimer’s.
Live Poll
Do you feel optimistic that new drug research will lead to effective Alzheimer's treatments?
